Physician profile
Kyle Anderson
NPI 1508459231
$2,842.86
in general payments reported to CMS, 2019-2025
33 companies · $763 in 2025
The $763 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $419 · 2022: $228 · 2023: $762 · 2024: $672 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,195.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $444.70 | 2021-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $418.45 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $260.93 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $235.82 | 2023-2025 | |
| Abbott Laboratories | $169.25 | 2024 | Freestyle Libre 3 |
| Boston Scientific Corporation | $131.50 | 2021 | |
| Phathom Pharmaceuticals, INC. | $123.55 | 2024 | Voquezna |
| Lilly USA, LLC | $121.81 | 2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $121.81 | 2025 | |
| Pfizer INC. | $86.29 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.90 | 2023-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $84.83 | 2021 | |
| Hologic Sales and Service, LLC | $60.67 | 2023 | Aptima |
| Sanofi Pasteur INC. | $50.80 | 2023-2025 | |
| Amgen INC. | $41.50 | 2024-2025 | Krystexxa, Otezla, Repatha |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $41.01 | 2024-2025 | |
| Horizon Therapeutics Plc | $40.89 | 2023 | Krystexxa |
| Daiichi Sankyo INC. | $38.15 | 2024-2025 | Injectafer |
| Dexcom, INC. | $30.05 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $29.11 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $28.34 | 2022 | |
| Glaxosmithkline, LLC. | $26.56 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $22.31 | 2021 | |
| Corcept Therapeutics | $20.25 | 2024 | Korlym |
| Lundbeck LLC | $19.24 | 2025 | Rexulti |
| Astellas Pharma US INC | $18.24 | 2023 | Veozah |
| Merck Sharp & Dohme LLC | $17.70 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $16.92 | 2023 | Eliquis |
| Phadia US INC. | $15.30 | 2025 | Immunocap |
| Qorumpartners | $13.55 | 2022 | |
| Alexion Pharmaceuticals, INC. | $12.52 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.97 | 2021 | |
| Genentech USA, INC. | $2.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.